Stock Market Update - July 13, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. VEEE - Twin Vee Powercats Co.
Price: $24.86 | Change: +415.77% ($20.04)
VEEE surged an incredible 415.77% around July 14, 2026, following news of a transformative strategic move. Twin Vee Powercats announced a definitive agreement to merge its publicly traded entity with USFM Corporation, a privately held company focused on mineral exploration in Greenland.
This isn't just a simple merger; it's a strategic separation designed to unlock shareholder value. While existing Twin Vee shareholders will receive a 10% stake in the new combined public company (which will focus on mineral interests), the original marine businesses – Twin Vee and Bahama Boat Works – are being privatized. They'll be transferred into a new private trust.
What makes this particularly interesting is that pre-merger stockholders will receive "Contingent Value Rights" (CVRs) in this trust. These CVRs entitle them to potential future distributions generated by the now-privately held marine business. So, shareholders essentially get a slice of a new mineral exploration venture and a chance to benefit from their original marine business operating independently for long-term growth away from public market pressures.
2. SOBR - SOBR Safe, Inc.
Price: $1.2 | Change: +176.75% ($0.7664)
SOBR witnessed a remarkable 176.75% gain around mid-July 2026, driven by a dramatic strategic pivot. SOBR Safe, Inc. announced it would cease its core alcohol monitoring business by the end of July, discontinuing its hardware and software operations like SOBRcheck and SOBRsafe. This move is projected to significantly reduce annual operating costs.
The primary catalyst for this surge was the planned merger with Clean World Ventures, Inc., a company focused on zero-carbon green energy technology manufacturing. Essentially, SOBR Safe is shedding its previous identity to transform into a player in distributed green hydrogen and clean electricity generation systems. This business combination is targeted for completion in the third quarter of 2026, contingent on various approvals.
What makes this particularly striking is the scale of the transformation: upon closing, Clean World Ventures shareholders are anticipated to own approximately 98.3% of the combined entity. This isn't just a pivot; it's a complete strategic overhaul, with the market reacting very positively to the company's planned shift into the green energy sector.
3. QTTB - Q32 Bio Inc.
Price: $21.38 | Change: +90.72% ($10.17)
QTTB soared with a 90.72% gain recently, thanks to exciting news from Q32 Bio Inc. The company announced very positive 36-week results from a key clinical trial for its experimental drug, bempikibart. This drug is designed to treat severe hair loss, known as alopecia areata.
The trial showed clinically meaningful hair regrowth and a strong safety profile for bempikibart, with patients experiencing significant reductions in scalp hair loss. These compelling results surpassed analyst expectations, leading firms like Wells Fargo and Oppenheimer to raise their price targets and upgrade QTTB's stock ratings.
Looking ahead, Q32 Bio plans to advance bempikibart into later-stage trials in the first half of 2027. To fund this, they're undertaking a $200 million public offering, a move that reflects significant confidence in the drug's future potential to address this condition.
4. AGEN - Agenus Inc.
Price: $6.12 | Change: +82.69% ($2.77)
AGEN surged a remarkable 82.69% around July 14, 2026, following two pivotal announcements from Agenus Inc. The biopharmaceutical company secured an oversubscribed private placement, raising an initial $85 million with the potential for up to $340 million upon full warrant exercise. This substantial funding is expected to support their operations, potentially through key milestones and into year-end 2031.
Alongside this financing, Agenus unveiled a strategic shift in its clinical development, prioritizing its lead drug combination, botensilimab and balstilimab (BOT+BAL). This combination will now focus on the pre-surgery treatment of high-risk colon cancer, with a planned global Phase 3 trial already aligned with FDA design elements. This focused approach aims to address a significant unmet medical need, representing a potential U.S. market opportunity exceeding $7 billion annually.
This combination of long-term financial security and a clear, focused development strategy, backed by positive early data for BOT+BAL, clearly boosted investor confidence. Analysts have also taken note, with H.C. Wainwright raising its price target on Agenus to $30 from $23, maintaining a 'Buy' rating.
5. FTRK - Fast Track Group
Price: $0.5931 | Change: +48.87% ($0.1947)
FTRK saw its stock price jump an impressive 48.87% recently, following a major strategic financing announcement. Fast Track Group secured a $1.5 million senior secured convertible note and a substantial $20 million equity line of credit from an institutional investor.
This significant capital infusion is earmarked to fuel the company's ambitious shift from a traditional agency model to one focused on owning intellectual property (IP) and long-term content monetization within the entertainment sector. Funds are planned for strategic partnerships, digital content development, and expanding their entertainment platforms. CEO Harris Lim highlighted that this funding offers greater flexibility to seize new opportunities.
What makes this particularly noteworthy is the choice of a convertible note structure, which allows Fast Track Group to access growth capital now without immediately diluting existing shares – a move management believes is prudent given their view that the stock is currently undervalued. This strategic financial move aims to strengthen their position in a rapidly evolving entertainment landscape.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.